Skip to search formSkip to main contentSkip to account menu

zalutumumab

Known as: HuMax-EGFr, 2F8 
A fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR is a cell surface… 
National Institutes of Health

Related topics

Related topics

4 relations
Antibody-Dependent Cellular CytotoxicityEGFR protein, humanantigen binding

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Dose escalation schedule for zalutumumab injections.
2013
2013
Histological features of hair follicles in skin biopsies and clinical features of patients treated with zalutumumab, zalutumumab + HuMab-10F8 or saline, based on evaluation of HE staining and…
2012
2012
Terapie nowotworowg øowy i szyi celowane molekularnie
Head and neck cancers (HNC) are 6th most common malignancies according to the incidence rate. Over 85% of tumors of this region… 
2009
2009
Antibody-Dependent Cellular Cytotoxicity Growth Factor Receptor Effectively Trigger Human IgG2 Antibodies against Epidermal
2009
2009
Compositions of recombinant antibodies from epidermal growth factor receptor
FIELD: chemistry. SUBSTANCE: invention relates to biochemistry and represents composition of antibodies for application in method…